Opinion|Videos|December 21, 2023

SEQUOIA: Biomarker Subgroup Analysis on Zanubrutinib in Treatment-Naïve CLL/SLL Without del(17p)

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Mazyar Shadman, MD, MPH

Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.

Episodes in this series

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 1 ALPINE: Zanubrutinib in Relapsed/Refractory CLL and SLL

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 2 SEQUOIA: Biomarker Subgroup Analysis on Zanubrutinib in Treatment-Naïve CLL/SLL Without del(17p)

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 3 SWOG S1826: Nivolumab-AVD in Older Patients with Advanced Hodgkin Lymphoma

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 4 Update from the POLARIX Study on Pola-R-CHP in DLBCL

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 5 Key Takeaways from ASH 2023 in Leukemia and Lymphoma

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

October 22nd, 2026

Choosing CLL Therapy Around Molecular Risk, Comorbidities, and Patient Preference

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

Trending on Targeted Onc

ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care

Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026

340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent

ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care

Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC